区域热疗联合顺铂加入吉西他滨对比吉西他滨用于已切除胰腺导管腺癌患者:HEAT随机临床试验
HEAT随机多中心开放标签试验将117例可评估的已切除胰腺导管腺癌患者随机分为GPH组(吉西他滨联合顺铂及区域热疗,57例)和G组(吉西他滨,60例)。中位随访56.6个月,中位无病生存期GPH组12.7个月对比G组11.2个月(p=0.394),无显著差异;GPH组复发后生存期显著延长(15.3个月对比9.8个月,p=0.031),中位总生存期33.2个月对比25.2个月(p=0.099),5年生存率28.4%对比18.7%。
要点
- 中位无病生存期GPH组12.7个月对比G组11.2个月,差异无统计学意义(p=0.394)。
- 中位复发后生存期GPH组15.3个月对比G组9.8个月,差异有统计学意义(p=0.031)。
- 中位总生存期GPH组33.2个月对比G组25.2个月(p=0.099),5年生存率28.4%对比18.7%。
核心结论
- HEAT随机对照试验未能证明GPH与G在无病生存期方面存在显著差异。
- 但结果提示复发后生存期存在差异,且总生存期有改善趋势。
- 在排除G组中8例由研究者决定额外接受卡培他滨的患者后,中位总生存期倾向于GPH组(p=0.052)。
研究设计与样本
- 随机、多中心、开放标签试验,将患者随机分配至GPH组或G组。
- GPH方案:吉西他滨1000 mg/m2于第1、15天给药,顺铂25 mg/m2联合区域热疗于第2、3、15、16天给药。
- G方案:吉西他滨1000 mg/m2于第1、8、15天给药。
- 两组均每四周重复,共六周期。
- 共117例可评估患者(中位年龄63岁)随机分配治疗,其中GPH组57例,G组60例。
主要发现
- 随访时间56.6个月时,中位无病生存期GPH组12.7个月对比G组11.2个月(p=0.394)。
- 中位复发后生存期GPH组15.3个月对比G组9.8个月,GPH组显著延长(p=0.031)。
- 中位总生存期GPH组33.2个月对比G组25.2个月(p=0.099),5年生存率GPH组28.4%对比G组18.7%。
- CTCAE 3级及以上不良事件发生率GPH组61.5%对比G组63.6%。
- G组有2例患者因治疗相关毒性死亡。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regional hyperthermia (RHT) with cisplatin added to gemcitabine showed efficacy in gemcitabine-pre-treated patients with advanced pancreatic ductal adenocarcinoma. We conducted a randomised clinical trial to investigate RHT with cisplatin added to gemcitabine (GPH) compared with gemcitabine (G) in the adjuvant setting of resected pancreatic ductal adenocarcinoma. METHODS: This randomised, multicentre, open-label trial randomly assigned patients to either GPH (gemcitabine 1000 mg/m2 on day 1, 15 and cisplatin 25 mg/m2 with RHT on day 2, 3 and 15,16) or to G (gemcitabine 1000 mg/m2 on day 1,8,15), four-weekly over six cycles. Disease-free survival (DFS) was the primary end-point. Secondary end-points included overall survival (OS) and safety. RESULTS: A total of 117 eligible patients (median age, 63 years) were randomly allocated to treatment (57 GPH; 60 G). With a follow-up time of 56.6 months, the median DFS was 12.7 compared to 11.2 months for GPH and G, respectively (p = 0.394). Median post-recurrence survival was significantly prolonged in the GPH-group (15.3 versus 9.8 months; p = 0.031). Median OS reached 33.2 versus 25.2 months (p = 0.099) with 5-year survival rates of 28.4% versus 18.7%. Excluding eight patients who received additional capecitabine in the G-arm (investigators choice), median OS favoured GPH (p = 0.052). Adverse events CTCAE (Common Terminology Criteria for Adverse Events) grade ≥3 occurred in 61.5% (GPH) versus 63.6% (G) of patients. Two patients in the G-group died because of treatment-related toxic effects. CONCLUSIONS: The randomised controlled Hyperthermia European Adjuvant Trial study failed to demonstrate a significant difference in DFS. However, it suggests a difference in post-recurrence survival and a trend for improved OS. CLINICALTRIALS: gov, number NCT01077427.
引用
- Issels RD, Boeck S, Pelzer U, et al. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial. Eur J Cancer. 2022. PMID: 36657324. doi:10.1016/j.ejca.2022.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。